دورية أكاديمية
Shedding light on PRAME expression in dysplastic nevi: a cohort study.
| العنوان: | Shedding light on PRAME expression in dysplastic nevi: a cohort study. |
|---|---|
| المؤلفون: | Innocenti L; Division of Pathology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126, Pisa, Italy., Scarpitta R; Division of Pathology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126, Pisa, Italy., Corraro S; Division of Pathology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126, Pisa, Italy., Ortenzi V; Department of Laboratory Medicine, Pisa University Hospital, 56126, Pisa, Italy., Bonadio AG; Department of Laboratory Medicine, Pisa University Hospital, 56126, Pisa, Italy., Loggini B; Department of Laboratory Medicine, Pisa University Hospital, 56126, Pisa, Italy., De Ieso K; Department of Laboratory Medicine, Pisa University Hospital, 56126, Pisa, Italy., Naccarato AG; Division of Pathology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126, Pisa, Italy.; Department of Laboratory Medicine, Pisa University Hospital, 56126, Pisa, Italy., Fanelli GN; Division of Pathology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126, Pisa, Italy.; Department of Laboratory Medicine, Pisa University Hospital, 56126, Pisa, Italy.; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, 10021, USA., Scatena C; Division of Pathology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126, Pisa, Italy. cristian.scatena@unipi.it.; Department of Laboratory Medicine, Pisa University Hospital, 56126, Pisa, Italy. cristian.scatena@unipi.it. |
| المصدر: | Virchows Archiv : an international journal of pathology [Virchows Arch] 2024 Jul; Vol. 485 (1), pp. 97-104. Date of Electronic Publication: 2023 Dec 19. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer International Country of Publication: Germany NLM ID: 9423843 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-2307 (Electronic) Linking ISSN: 09456317 NLM ISO Abbreviation: Virchows Arch Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Berlin ; New York : Springer International, c1994- |
| مواضيع طبية MeSH: | Dysplastic Nevus Syndrome*/pathology , Dysplastic Nevus Syndrome*/metabolism , Antigens, Neoplasm*/analysis , Antigens, Neoplasm*/metabolism , Antigens, Neoplasm*/biosynthesis , Skin Neoplasms*/pathology , Skin Neoplasms*/metabolism , Melanoma*/pathology , Melanoma*/metabolism , Melanoma*/diagnosis , Biomarkers, Tumor*/analysis, Humans ; Male ; Female ; Middle Aged ; Adult ; Aged ; Nevus, Pigmented/pathology ; Nevus, Pigmented/metabolism ; Cohort Studies ; Immunohistochemistry ; Young Adult ; Aged, 80 and over ; Melanoma, Cutaneous Malignant ; Adolescent ; Diagnosis, Differential |
| مستخلص: | Dysplastic nevi represent one of the least agreed-upon entities in dermatopathology despite the existence of established criteria. This study explores preferentially expressed antigen in melanoma (PRAME) in dysplastic nevi, an uncharted area. We examined 22 common melanocytic nevi (CMN), 20 cutaneous melanomas (CM), 48 low-grade dysplastic nevi (LG-DN), and 40 high-grade dysplastic nevi (HG-DN). PRAME was immunohistochemically assessed using a five-tiered system (0 to 4 +). Among CMN, 59% scored 0, 32% scored 1 + , and 9% scored 2 + . CM had score 2 + and 4 + in 11% and 89% of cases, respectively. Among LG-DN, 38% presented score 0, 31% score 1 + , 17% score 2 + , 8% score 3 + , and 6% score 4 + . Thirty per cent of HG-DN demonstrated a score 0, 30% with score 1 + , 15% score 2 + , 10% score 3 + , and 15% score 4 + . Compared to CMN and CM, LG-DN and HG-DN showed heterogeneous expression profiles of PRAME. PRAME positivity effectively distinguished HG-DN from CM with 85% specificity and 80% sensitivity (p < 0.0001). Predictive values were 87% (negative) and 76% (positive). Furthermore, a trend of increased PRAME expression from LG-DN to HG-DN was observed. However, the applicability of PRAME in the differential diagnosis of dysplastic lesions remains unclear as can yield conflicting results with morphology, which remains the primary diagnostic tool for melanocytic lesions. (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.) |
| References: | Drozdowski R, Spaccarelli N, Peters MS, Grant-Kels JM (2023) Dysplastic nevus part I: historical perspective, classification, and epidemiology. J Am Acad Dermatol 88:1–10. https://doi.org/10.1016/j.jaad.2022.04.068. (PMID: 10.1016/j.jaad.2022.04.06836038073) Elder DE (2010) Dysplastic naevi: an update. Histopathology 56:112–120. https://doi.org/10.1111/j.1365-2559.2009.03450.x. (PMID: 10.1111/j.1365-2559.2009.03450.x20055909) Shors AR, Kim S, White E et al (2006) Dysplastic naevi with moderate to severe histological dysplasia: a risk factor for melanoma: dysplastic naevi and melanoma. Br J Dermatol 155:988–993. https://doi.org/10.1111/j.1365-2133.2006.07466.x. (PMID: 10.1111/j.1365-2133.2006.07466.x17034530) Elder DE, Bastian BC, Cree IA et al (2020) The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch Pathol Lab Med 144:500–522. https://doi.org/10.5858/arpa.2019-0561-RA. (PMID: 10.5858/arpa.2019-0561-RA32057276) Aydin Ulgen O, Yıldız P, Acar HC, Demirkesen C (2022) Analysis of interobserver reproducibility in grading dysplastic nevi: results of the application of the 2018 World Health Organization grading criteria. J Cutan Pathol 49:343–349. https://doi.org/10.1111/cup.14165. (PMID: 10.1111/cup.1416534758119) Nobre AB, Piñeiro-Maceira J, Raggio Luiz R (2013) Analysis of interobserver reproducibility in grading histological patterns of dysplastic nevi*. An Bras Dermatol 88:23–31. https://doi.org/10.1590/S0365-05962013000100002. (PMID: 10.1590/S0365-05962013000100002235390003699937) Ikeda H, Lethé B, Lehmann F et al (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199–208. https://doi.org/10.1016/S1074-7613(00)80426-4. (PMID: 10.1016/S1074-7613(00)80426-49047241) Wadelin F, Fulton J, McEwan PA et al (2010) Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia. Mol Cancer 9:226. https://doi.org/10.1186/1476-4598-9-226. (PMID: 10.1186/1476-4598-9-226207999512936344) Liu Z, Li M, Jiang Z, Wang X (2018) A comprehensive immunologic portrait of triple-negative breast cancer. Transl Oncol 11:311–329. https://doi.org/10.1016/j.tranon.2018.01.011. (PMID: 10.1016/j.tranon.2018.01.011294137655884188) Xu Y, Zou R, Wang J et al (2020) The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer. Cell Prolif 53. https://doi.org/10.1111/cpr.12770. Šafanda A, Kendall Bártů M, Michálková R et al (2023) Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors. Virchows Arch. https://doi.org/10.1007/s00428-023-03629-z. (PMID: 10.1007/s00428-023-03629-z37610627) Hedrich V, Breitenecker K, Ortmayr G et al (2023) PRAME is a novel target of tumor-intrinsic Gas6/Axl activation and promotes cancer cell invasion in hepatocellular carcinoma. Cancers 15:2415. https://doi.org/10.3390/cancers15092415. (PMID: 10.3390/cancers150924153717388210177160) Kern CH, Yang M, Liu W-S (2021) The PRAME family of cancer testis antigens is essential for germline development and gametogenesis. Biol Reprod 105:290–304. https://doi.org/10.1093/biolre/ioab074. (PMID: 10.1093/biolre/ioab07433880503) Schenk T, Stengel S, Goellner S et al (2007) Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies. Genes Chromosomes Cancer 46:796–804. https://doi.org/10.1002/gcc.20465. (PMID: 10.1002/gcc.2046517534929) Epping MT, Wang L, Edel MJ et al (2005) The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122:835–847. https://doi.org/10.1016/j.cell.2005.07.003. (PMID: 10.1016/j.cell.2005.07.00316179254) Neuhaus N (2016) PRAME as diagnostic marker and as regulator for cell fate decisions in germ cell cancers. Br J Cancer 115:401–402. https://doi.org/10.1038/bjc.2016.217. (PMID: 10.1038/bjc.2016.217274414974985358) Alomari AK, Tharp AW, Umphress B, Kowal RP (2021) The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors. J Cutan Pathol 48:1115–1123. https://doi.org/10.1111/cup.14000. (PMID: 10.1111/cup.1400033660310) Lezcano C, Jungbluth AA, Nehal KS et al (2018) PRAME expression in melanocytic tumors. Am J Surg Pathol 42:1456–1465. https://doi.org/10.1097/PAS.0000000000001134. (PMID: 10.1097/PAS.0000000000001134300450646631376) Raghavan SS, Wang JY, Kwok S et al (2020) PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features. J Cutan Pathol 47:1123–1131. https://doi.org/10.1111/cup.13818. (PMID: 10.1111/cup.1381832700786) Fattori A, de la Fouchardière A, Cribier B, Mitcov M (2022) Preferentially expressed antigen in melanoma immunohistochemistry as an adjunct for evaluating ambiguous melanocytic proliferation. Hum Pathol 121:19–28. https://doi.org/10.1016/j.humpath.2021.12.008. (PMID: 10.1016/j.humpath.2021.12.00834990622) Cazzato G, Cascardi E, Colagrande A et al (2022) PRAME immunoexpression in 275 cutaneous melanocytic lesions: a double institutional experience. Diagnostics 12:2197. https://doi.org/10.3390/diagnostics12092197. (PMID: 10.3390/diagnostics12092197361405979498170) Ricci C, Dika E, Ambrosi F et al (2022) Cutaneous melanomas: a single center experience on the usage of immunohistochemistry applied for the diagnosis. Int J Mol Sci 23:5911. https://doi.org/10.3390/ijms23115911. (PMID: 10.3390/ijms23115911356825899180684) Lohman ME, Steen AJ, Grekin RC, North JP (2021) The utility of PRAME staining in identifying malignant transformation of melanocytic nevi. J Cutan Pathol 48:856–862. https://doi.org/10.1111/cup.13958. (PMID: 10.1111/cup.1395833433032) Gradecki SE, Valdes-Rodriguez R, Wick MR, Gru AA (2021) PRAME immunohistochemistry as an adjunct for diagnosis and histological margin assessment in lentigo maligna. Histopathology 78:1000–1008. https://doi.org/10.1111/his.14312. (PMID: 10.1111/his.1431233280156) Lezcano C, Pulitzer M, Moy AP et al (2020) Immunohistochemistry for PRAME in the distinction of nodal nevi from metastatic melanoma. Am J Surg Pathol 44:503–508. https://doi.org/10.1097/PAS.0000000000001393. (PMID: 10.1097/PAS.0000000000001393316334887071962) Koch EAT, Erdmann M, Berking C et al (2023) Standardized computer-assisted analysis of prame immunoreactivity in dysplastic nevi and superficial spreading melanomas. Int J Mol Sci 24:6388. https://doi.org/10.3390/ijms24076388. (PMID: 10.3390/ijms240763883704736110094429) Zhu H, Wang J, Yin J et al (2018) Downregulation of PRAME suppresses proliferation and promotes apoptosis in hepatocellular carcinoma through the activation of p53 mediated pathway. Cell Physiol Biochem 45:1121–1135. https://doi.org/10.1159/000487353. (PMID: 10.1159/00048735329439259) Kewitz S, Staege MS (2013) Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells. PLoS ONE 8:e55897. https://doi.org/10.1371/journal.pone.0055897. (PMID: 10.1371/journal.pone.0055897234090803569423) Borden ES, Adams AC, Buetow KH et al (2021) Shared gene expression and immune pathway changes associated with progression from nevi to melanoma. Cancers 14:3. https://doi.org/10.3390/cancers14010003. (PMID: 10.3390/cancers14010003350081678749980) Gassenmaier M, Hahn M, Metzler G et al (2021) Diffuse PRAME expression is highly specific for thin melanomas in the distinction from severely dysplastic nevi but does not distinguish metastasizing from non-metastasizing thin melanomas. Cancers 13:3864. https://doi.org/10.3390/cancers13153864. (PMID: 10.3390/cancers13153864343597658345662) Lezcano C, Jungbluth AA, Busam KJ (2020) Comparison of immunohistochemistry for PRAME with cytogenetic test results in the evaluation of challenging melanocytic tumors. Am J Surg Pathol 44:893–900. https://doi.org/10.1097/PAS.0000000000001492. (PMID: 10.1097/PAS.0000000000001492323176057289661) Goto K, Yoshikawa S, Takai T et al (2023) Clinicopathologic and genetic characterization of invasive melanoma with BRAF V600K mutation: a study of 16 cases. J Cutan Pathol 50:739–747. https://doi.org/10.1111/cup.14470. (PMID: 10.1111/cup.1447037226844) Nasimi M, Ghanadan A, Kamyab K et al (2021) Prevalence and main determinants of BRAF V600E mutation in dysplastic and congenital nevi. Iran J Pathol 16:51–56. https://doi.org/10.30699/ijp.2020.130968.2451. (PMID: 10.30699/ijp.2020.130968.245133391380) Kiuru M, Tartar DM, Qi L et al (2018) Improving classification of melanocytic nevi: association of BRAF V600E expression with distinct histomorphologic features. J Am Acad Dermatol 79:221–229. https://doi.org/10.1016/j.jaad.2018.03.052. (PMID: 10.1016/j.jaad.2018.03.052296532126090558) Muse ME, Bergman DT, Salas LA et al (2022) Genome-scale DNA methylation analysis identifies repeat element alterations that modulate the genomic stability of melanocytic nevi. J Invest Dermatol 142:1893-1902.e7. https://doi.org/10.1016/j.jid.2021.11.025. (PMID: 10.1016/j.jid.2021.11.02534871578) |
| فهرسة مساهمة: | Keywords: Dermatopathology; Differential diagnosis; Dysplastic nevi; Immunohistochemistry; Melanoma; PRAME |
| المشرفين على المادة: | 0 (PRAME protein, human) 0 (Antigens, Neoplasm) 0 (Biomarkers, Tumor) |
| تواريخ الأحداث: | Date Created: 20231219 Date Completed: 20240719 Latest Revision: 20240719 |
| رمز التحديث: | 20240719 |
| DOI: | 10.1007/s00428-023-03720-5 |
| PMID: | 38112793 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1432-2307 |
|---|---|
| DOI: | 10.1007/s00428-023-03720-5 |